Nanotechnology in the Treatment of Inflammatory Bowel Disease

被引:25
|
作者
Giron, Fanny [1 ]
Pasto, Anna [2 ]
Tasciotti, Ennio [3 ,4 ]
Abraham, Bincy P. [3 ,4 ]
机构
[1] Univ Catolica Honduras, San Pedro Sula, Honduras
[2] Ist Oncol Veneto IRCCS, Padua, Italy
[3] Houston Methodist Hosp, Underwood Ctr Digest Disorders, Houston, TX 77030 USA
[4] Houston Methodist Hosp, Houston Methodist Res Inst, Houston, TX 77030 USA
关键词
inflammatory bowel disease; nanoparticles; leukosomes; drug delivery; treatment; PH-SENSITIVE NANOPARTICLES; VASOACTIVE-INTESTINAL-PEPTIDE; IMMUNE-REGULATING CELLS; COLON-SPECIFIC DELIVERY; TNBS-INDUCED COLITIS; DRUG-DELIVERY; IN-VIVO; 5-AMINOSALICYLIC ACID; ULCERATIVE-COLITIS; TRIPEPTIDE KPV;
D O I
10.1093/ibd/izz205
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Due to the lack of cure for inflammatory bowel disease (IBD) and failure of current medical therapies in many patients with IBD, a need exists in finding novel ways to treat inflammation with a high benefit and the lowest risk possible. With current medical therapies, adverse events or risks of cancer/lymphoma and infections prevent patients-and sometimes providers-in using effective therapies for treatment. Some patients develop systemic side effects that preclude them from continuing a therapy that may have been efficacious, or in other cases, current medical therapies are not adequate to control disease. Nanotechnology is an emerging field where particles, in the size of nanometers, can be used to deliver medications directly to the area of inflammation thus avoiding drug-associated systemic side effects. When using nanoparticles (NPs), only a small amount of the drug is needed, and it can be delivered directly to the inflamed site without exposure to the rest of the body. Here we review conventional and unconventional therapies applied in the treatment of IBD underlying how the introduction of NPs has improved their safety and efficacy.
引用
收藏
页码:1871 / 1880
页数:10
相关论文
共 50 条
  • [11] Nanotherapeutics for the treatment of inflammatory bowel disease
    Chen, Qiubing
    Xiao, Bo
    Merlin, Didier
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (06) : 495 - 497
  • [12] Pharmacogenomics in the treatment of inflammatory bowel disease
    Smith, Melissa A.
    Marinaki, Anthony M.
    Sanderson, Jeremy D.
    PHARMACOGENOMICS, 2010, 11 (03) : 421 - 437
  • [13] Treatment of inflammatory bowel disease with antibiotics
    Isaacs, KL
    Sartor, RB
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (02) : 335 - +
  • [14] Treatment of inflammatory bowel disease (IBD)
    Pithadia, Anand B.
    Jain, Sunita
    PHARMACOLOGICAL REPORTS, 2011, 63 (03) : 629 - 642
  • [15] Alicaforsen for the treatment of inflammatory bowel disease
    Jairath, Vipul
    Khanna, Reena
    Feagan, Brian G.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (08) : 991 - 997
  • [16] Mesalazine for the treatment of inflammatory bowel disease
    Criscuoli, Valeria
    Modesto, Irene
    Orlando, Ambrogio
    Cottone, Mario
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (12) : 1669 - 1678
  • [17] Treatment of inflammatory bowel disease in childhood
    Escher, JC
    Taminiau, JAJM
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2001, 36 : 48 - 50
  • [18] Rifaximin in the treatment of inflammatory bowel disease
    Mario Guslandi
    World Journal of Gastroenterology, 2011, 17 (42) : 4643 - 4646
  • [19] Surgical treatment of inflammatory bowel disease
    Fazio, VW
    Strong, SA
    CURRENT OPINION IN GASTROENTEROLOGY, 1997, 13 (04) : 317 - 324
  • [20] The Treatment of Pediatric Inflammatory Bowel Disease
    Kim, Kyung Mo
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2008, 11 : 72 - 79